Cvrx Inc. is a medical technology company focused on developing and commercializing innovative solutions for the treatment of cardiovascular diseases
The company specializes in advancing minimally invasive therapies that aim to improve heart function and enhance the quality of life for patients suffering from conditions such as heart failure. By leveraging cutting-edge technology and research, Cvrx Inc. is dedicated to addressing the unmet needs in the cardiovascular space and providing healthcare professionals with effective tools to manage patient care. Through its commitment to innovation, the company strives to make a meaningful impact in the field of cardiology and transform patient outcomes.
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arhaus, Inc (NASDAQ: ARHS), Cardlytics, Inc. (NASDAQ: CDLX), and CVRx, Inc. (NASDAQ: CVRX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CVRx, Inc. (“CVRx” or the “Company”) (NASDADQ: CVRX) on behalf of CVRx stockholders. Our investigation concerns whether CVRx has violated the federal securities laws and/or engaged in other unlawful business practices.
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX) for violations of the securities laws.
